FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593443444> ?p ?o ?g. }

• W2593443444 endingPage "194" @default.
• W2593443444 startingPage "194" @default.
• W2593443444 abstract "Abstract The Multiple Myeloma Research Foundation (MMRF) CoMMpass trial (NCT145429) is a longitudinal study of 1147 patients with newly-diagnosed multiple myeloma from clinical sites in the United States, Canada, Spain, and Italy. Each patient receives a treatment regimen containing a proteasome inhibitor, immunomodulatory agent, or both. Clinical parameters are collected at study enrollment and every three months through the eight-year observation period. To identify molecular determinants of clinical outcome each baseline and progression tumor specimen is characterized using Whole Genome Sequencing, Exome Sequencing, and RNA sequencing. Data available as of January 1, 2016 is included in this first formal interim analysis, which includes 995 enrolled patients of whom 851 are molecularly characterized. This cohort of patients includes 74 patients with at least two sequential samples, plus 15 patients with characterized tumor samples from the bone marrow and peripheral blood. The median follow-up of the cohort is 66 weeks, which identified a median PFS of 36 months for the cohort. The median OS was not reached but 76% are still alive at 3 years. Although the age at enrollment by gender is uniform, there is a significant difference in PFS and OS, with males performing worse than females, p=0.001 and p=0.0004 respectively. Analysis of the exome sequencing data from the 746 baseline BM localized tumors identified a median of 122 non-immunoglobulin related mutations per patient, with an interquartile range of 96-155. There is a group of highly mutated (>481 mutations [mean+1SD]) patients who frequently have MAF family translocations (66%) and/or mutations in the DNA repair genes MSH2, MSH3, MSH4, MSH6, or ATM (38%). Across the cohort 21/53 of the DNA repair gene mutations reside in these 21 patients compared to 14/47 MAF family translocations. Analysis of the somatic mutations identified 20 significant genes, which are recurrently mutated and the mutated allele is detectably expressed; BRAF, CYLD, DIS3, FAM46C, FCF1, FGFR3, FUBP1, KRAS, MAX, NFKBIA, NRAS, PRKD2, RASA2, RB1, SAMHD1, SP140, TGDS, TP53, TRAF2, and TRAF3. Integration of the copy number data and the mutation data identified an association between TP53 deletion and mutation, suggesting many patients present with homozygous loss of TP53. Patients with one or two functional TP53 alleles had similar PFS and OS but the patients with zero functional alleles had a significantly reduced OS (p<0.05). Therefore, the existing association between 17p deletion and outcome is driven by the subpopulation of patients with bi-allelic TP53 loss. Analysis of the whole genome sequencing data available from the 719 baseline BM localized tumors for immunoglobulin translocations identified the expected canonical translocations along with events targeting MYC in 14.6% of patients. Unlike the canonical translocations the MYC translocations are enriched in hyperdiploid tumors (22.3%) and often involve light chain loci, particularly the lambda locus. Within the hyperdiploid patients, those with a MYC translocation have a reduced PFS. To identify molecular subtypes we performed unsupervised clustering using a consensus clustering approach on the 613 baseline BM tumors with RNA sequencing data, which identified 12 distinct subtypes. This analysis confirmed previous studies identifing distinct subtypes associated with WHSC1, MAF/MAFA/MAFB translocations and two subtypes associated with CCND1/CCND2/CCND3 subtypes, which can be separated by CD20 expression. Five subtypes are associated with hyperdiploid myeloma, one group is nearly devoid of chromosome 11 gains while this event is ubiquitous in the remaining hyperdiploid groups. The genomic profiles of the paired tumors isolated from the peripheral blood and bone marrow share 87% of the observed events with unique events being more common in the PB compartment suggesting the PB compartments are often derived from a closely related progenitor clone of the bulk BM tumor. Applying our bayesian clonal analysis method to the serial samples identified multiple clones in all patients with some showing no changes in clonal populations while the majority show significant shifts in clonal burden. These analyses have identified tumor initiating mutations and new subtypes of myeloma, which are associated with distinct molecular events and clinical outcomes. Disclosures Niesvizky: Celgene: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Research Funding, Speakers Bureau; Onyx: Consultancy, Research Funding, Speakers Bureau. Wolf:Takeda: Honoraria; Telomere Diagnostics: Consultancy; Amgen: Honoraria; Celgene: Honoraria; Pharmacyclics: Honoraria. Lonial:Onyx: Consultancy; BMS: Consultancy; Novartis: Consultancy; Janssen: Consultancy; Janssen: Consultancy; Merck: Consultancy; Onyx: Consultancy; Celgene: Consultancy; Millenium: Consultancy; Novartis: Consultancy; BMS: Consultancy; Celgene: Consultancy." @default.
• W2593443444 created "2017-03-16" @default.
• W2593443444 creator A5000508881 @default.
• W2593443444 creator A5008702162 @default.
• W2593443444 creator A5011954777 @default.
• W2593443444 creator A5023276777 @default.
• W2593443444 creator A5026151069 @default.
• W2593443444 creator A5028046297 @default.
• W2593443444 creator A5030868239 @default.
• W2593443444 creator A5034738723 @default.
• W2593443444 creator A5038877506 @default.
• W2593443444 creator A5040257305 @default.
• W2593443444 creator A5043014546 @default.
• W2593443444 creator A5043351209 @default.
• W2593443444 creator A5046191778 @default.
• W2593443444 creator A5047866471 @default.
• W2593443444 creator A5049554397 @default.
• W2593443444 creator A5055000089 @default.
• W2593443444 creator A5059120463 @default.
• W2593443444 creator A5060909278 @default.
• W2593443444 creator A5062576646 @default.
• W2593443444 creator A5062903810 @default.
• W2593443444 creator A5076684937 @default.
• W2593443444 creator A5077846750 @default.
• W2593443444 creator A5080153561 @default.
• W2593443444 creator A5080909130 @default.
• W2593443444 creator A5080927178 @default.
• W2593443444 creator A5084431592 @default.
• W2593443444 creator A5085850492 @default.
• W2593443444 creator A5086187792 @default.
• W2593443444 creator A5086345082 @default.
• W2593443444 creator A5088292582 @default.
• W2593443444 creator A5090712632 @default.
• W2593443444 date "2016-12-02" @default.
• W2593443444 modified "2023-10-02" @default.
• W2593443444 title "Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study" @default.
• W2593443444 doi "https://doi.org/10.1182/blood.v128.22.194.194" @default.
• W2593443444 hasPublicationYear "2016" @default.
• W2593443444 type Work @default.
• W2593443444 sameAs 2593443444 @default.
• W2593443444 citedByCount "10" @default.
• W2593443444 countsByYear W25934434442017 @default.
• W2593443444 countsByYear W25934434442018 @default.
• W2593443444 countsByYear W25934434442020 @default.
• W2593443444 countsByYear W25934434442021 @default.
• W2593443444 countsByYear W25934434442022 @default.
• W2593443444 countsByYear W25934434442023 @default.
• W2593443444 crossrefType "journal-article" @default.
• W2593443444 hasAuthorship W2593443444A5000508881 @default.
• W2593443444 hasAuthorship W2593443444A5008702162 @default.
• W2593443444 hasAuthorship W2593443444A5011954777 @default.
• W2593443444 hasAuthorship W2593443444A5023276777 @default.
• W2593443444 hasAuthorship W2593443444A5026151069 @default.
• W2593443444 hasAuthorship W2593443444A5028046297 @default.
• W2593443444 hasAuthorship W2593443444A5030868239 @default.
• W2593443444 hasAuthorship W2593443444A5034738723 @default.
• W2593443444 hasAuthorship W2593443444A5038877506 @default.
• W2593443444 hasAuthorship W2593443444A5040257305 @default.
• W2593443444 hasAuthorship W2593443444A5043014546 @default.
• W2593443444 hasAuthorship W2593443444A5043351209 @default.
• W2593443444 hasAuthorship W2593443444A5046191778 @default.
• W2593443444 hasAuthorship W2593443444A5047866471 @default.
• W2593443444 hasAuthorship W2593443444A5049554397 @default.
• W2593443444 hasAuthorship W2593443444A5055000089 @default.
• W2593443444 hasAuthorship W2593443444A5059120463 @default.
• W2593443444 hasAuthorship W2593443444A5060909278 @default.
• W2593443444 hasAuthorship W2593443444A5062576646 @default.
• W2593443444 hasAuthorship W2593443444A5062903810 @default.
• W2593443444 hasAuthorship W2593443444A5076684937 @default.
• W2593443444 hasAuthorship W2593443444A5077846750 @default.
• W2593443444 hasAuthorship W2593443444A5080153561 @default.
• W2593443444 hasAuthorship W2593443444A5080909130 @default.
• W2593443444 hasAuthorship W2593443444A5080927178 @default.
• W2593443444 hasAuthorship W2593443444A5084431592 @default.
• W2593443444 hasAuthorship W2593443444A5085850492 @default.
• W2593443444 hasAuthorship W2593443444A5086187792 @default.
• W2593443444 hasAuthorship W2593443444A5086345082 @default.
• W2593443444 hasAuthorship W2593443444A5088292582 @default.
• W2593443444 hasAuthorship W2593443444A5090712632 @default.
• W2593443444 hasConcept C104317684 @default.
• W2593443444 hasConcept C10590036 @default.
• W2593443444 hasConcept C119060515 @default.
• W2593443444 hasConcept C126322002 @default.
• W2593443444 hasConcept C141071460 @default.
• W2593443444 hasConcept C143998085 @default.
• W2593443444 hasConcept C144301174 @default.
• W2593443444 hasConcept C16671776 @default.
• W2593443444 hasConcept C2776364478 @default.
• W2593443444 hasConcept C2777478702 @default.
• W2593443444 hasConcept C2781413609 @default.
• W2593443444 hasConcept C38180746 @default.
• W2593443444 hasConcept C501734568 @default.
• W2593443444 hasConcept C535046627 @default.
• W2593443444 hasConcept C54355233 @default.
• W2593443444 hasConcept C61943457 @default.
• W2593443444 hasConcept C71924100 @default.
• W2593443444 hasConcept C72563966 @default.
• W2593443444 hasConcept C86803240 @default.

• next